The need for better psoriasis treatments has been long-standing for years. Now, options for effective psoriasis relief have multiplied. Due to these recent developments, 8 million Americans and 30 million people worldwide with psoriasis have reason for optimism. Patients affected by this skin disease span all ages and genders, often having a family history of the condition and many times having an associated risk factor like obesity, smoking, and alcohol use. Regardless of your circumstances, if you have psoriasis, you deserve to be introduced to the new psoriasis medication.
Current treatments for psoriasis
Psoriasis is not a uniform disease. Variants include plaque psoriasis with thick, scaly areas, guttate psoriasis with temporary outbreaks, inverse psoriasis that affects skin folds, and pustular psoriasis that can be generalized or limited to the palms and soles. Associated conditions like psoriatic arthritis can be part of the picture, too.
Treatment options are diverse as well. Topical therapies, like corticosteroids, emollients, and retinoids, have traditionally attacked this disease via anti-inflammatory mechanisms, moisturization, or inhibition of skin cell proliferation, respectively. Systemic oral and injectable treatments, like methotrexate and biologics, target aspects of the immune system to reduce inflammation.
Problems with existing psoriasis treatments
The problem with pre-existing psoriasis treatments has been that the relatively safe topical options weren’t always effective. Immunosuppressants like early biologics risked a multitude of serious side effects. Hence, the search was on for new medication for psoriasis that combined tolerability with high efficacy.
Newly approved psoriasis medication
In the past two years, new topical and systemic agents have been added to the list of options for psoriasis management. Their advantages are significant for individuals looking for a new treatment for psoriasis.
Vtama
Approved by the Food and Drug Administration (FDA) in 2022 for use in adults, Vtama (tapinarof) is a topical cream that treats plaque psoriasis by decreasing inflammation. It accomplishes this by modifying interleukin 17 (IL-17) cytokines, which are the immune system’s messenger proteins. Vtama offers another topical treatment option to help avoid the topical corticosteroid side effect of skin atrophy or thinning.
Zoryve
Zoryve (roflumilast) is also a topical cream for plaque psoriasis in adults. It, too, got approval from the FDA in 2022. The drug’s mechanism of action as a phosphodiesterase 4 inhibitor means it is not a steroid. This important distinction allows it to be used in skin folds, unlike topical steroids, which cannot be used due to skin atrophy side effects.
Sotyktu
By inhibiting tyrosine kinase 2, and thereby modifying cytokines like interleukin 23, Sotyktu (deucravacitinib) acts as an effective anti-inflammatory treatment for moderate-to-severe plaque psoriasis. The FDA approved this oral tablet as an anti-psoriatic medication in 2022. Clinical trials leading to its approval demonstrated efficacy and safety.
Bimzelx
Bimzelx (bimekizumab) is a monoclonal antibody that inhibits IL-17 to reduce psoriasis inflammation. The treatment requires a subcutaneous injection every four weeks for 16 weeks, and then every eight weeks thereafter. FDA approval was granted in 2023 for moderate to severe plaque psoriasis in adults.
Compare new psoriasis medications
According to the medical reference UpToDate, psoriasis medications come in various formulations, with most all aiming to reduce the inflammatory cascade in psoriasis. Reviewing and comparing options may help you narrow down which new medication for psoriasis to consult your healthcare provider about.
Common psoriasis medications |
||||
---|---|---|---|---|
Drug name | Drug class | Form | Safety & side effect highlights | SingleCare savings |
Clobex (clobetasol) 0.05% liquid | Corticosteroid | Topical | Skin atrophy with extended use | Get Clobex coupon |
Vanos (fluocinonide) 0.1% cream | Corticosteroid | Topical | Skin atrophy with extended use | Get Vanos coupon |
Sorilux (calcipotriene) foam | Vitamin D analog | Topical | Skin irritation | Get Sorilux coupon |
Calcitriol ointment | Vitamin D analog | Topical | Skin irritation | Get calcitriol coupon |
Psoriasin (tar) | Coal tar | Topical | Can stain skin, hair, and clothing; unpleasant odor | Get Psoriasin coupon |
Tazorac (tazarotene) cream | Retinoid | Topical | Skin irritation, sun sensitivity, avoid in pregnancy and breastfeeding | Get Tazorac coupon |
Tacrolimus 0.1% ointment | Calcineurin inhibitor | Topical | Avoids skin atrophy but has an FDA boxed warning about lymphoma risk, although studies have not confirmed the risk | Get tacrolimus coupon |
Elidel (pimecrolimus) 1% cream | Calcineurin inhibitor | Topical | Avoids skin atrophy but has an FDA boxed warning about lymphoma risk, although studies have not confirmed the risk | Get Elidel coupon |
Vtama (tapinarof) 0.1% cream | Aryl hydrocarbon receptor-modulating agent | Topical | Skin rash, headache | Get Vtama coupon |
Zoryve (roflumilast) 0.3% cream | Phosphodiesterase 4 inhibitor | Topical | Diarrhea, headache | Get Zoryve coupon |
Methotrexate tablets | Folic acid antagonist | Oral | Multiple FDA warnings, including liver toxicity, lung toxicity, intestinal toxicity, reduced clearance with kidney disease, increased infection risk, and severe skin and allergic reactions | Get methotrexate coupon |
Acitretin capsules | Retinoid | Oral | Multiple FDA warnings including liver toxicity, strict avoidance in pregnancy, strict precautions against pregnancy in women of childbearing age, avoidance of alcohol by women while taking, and avoidance of blood donation during and for at least 3 years after treatment | Get acitretin coupon |
Neoral (cyclosporine) tablets | T cell immune suppressant | Oral | Multiple FDA warnings including kidney toxicity, increased infection and cancer risk, and hypertension risk | Get Neoral coupon |
Otezla (apremilast) tablets | Phosphodiesterase 4 inhibitor | Oral | Diarrhea, nausea, headache, depression, and weight loss | Get Otezla coupon |
Enbrel (etanercept) injection | TNF-alpha inhibitor | Subcutaneous injection | FDA warnings regarding increased infection and cancer risk | Get Enbrel coupon |
Remicade (infliximab) injection | TNF-alpha inhibitor | Intravenous infusion | FDA warnings regarding increased infection and cancer risk | Get a SingleCare discount card |
Humira (adalimumab) injection | TNF-alpha inhibitor | Subcutaneous injection | FDA warnings regarding increased infection and cancer risk | Get Humira coupon |
Cimzia (certolizumab) injection | TNF-alpha inhibitor | Subcutaneous injection | FDA warnings regarding increased infection and cancer risk | Get Cimzia coupon |
Cosentyx (secukinumab) injection | IL-17A inhibitor | Subcutaneous injection | Diarrhea, infection risk, low immune cell count, severe eczema, inflammatory bowel disease | Get SingleCare discount card |
Taltz (ixekizumab) injection | IL-17A inhibitor | Subcutaneous injection | Nausea, infection risk, low immune or clotting cell count, inflammatory bowel disease | Get SingleCare discount card |
Siliq (brodalumab)
injection |
IL-17A inhibitor | Subcutaneous injection | FDA warning about suicidality, diarrhea, infection risk, inflammatory bowel disease | Get Siliq coupon |
Bimzelx (bimekizumab) | IL-17A and IL-17F inhibitor | Subcutaneous injection | FDA warning about suicidality, headache, infection risk, inflammatory bowel disease | Get Bimzelx coupon |
Stelara (ustekinumab) injection | IL-23 inhibitor | Subcutaneous injection | Infection risk, cancer risk, headache, diarrhea | Get SingleCare discount card |
Tremfya (guselkumab) injection | IL-23 inhibitor | Subcutaneous injection | Infection risk, headache, joint pains | Get Tremfya coupon |
Ilumya (tildrakizumab) injection | IL-23 inhibitor | Subcutaneous injection | Infection risk, diarrhea | Get SingleCare discount card |
Skyrisi (risankizumab) injection | IL-23 inhibitor | Subcutaneous injection | Infection risk, joint pain, headache, anemia | Get Skyrizi coupon |
Sotyktu (deucravacitinib) tablets | Tyrosine kinase inhibitor | Oral | Infection risk, muscle enzyme elevation, triglyceride elevation | Get Sotyktu coupon |
Ask your healthcare provider about new psoriasis medication
The plethora of new treatments for psoriasis is impressive when compared with the options available twenty years ago. Considering how the drugs are administered and what side effects are risked can make it easier to narrow down the list to a few options that you might feel comfortable trying. Have a conversation with your healthcare provider to review more details about the new psoriasis medication on the market and make the best choice together.
Sources
- Psoriasis statistics, National Psoriasis Foundation (NPF) (2022)
- Psoriasis: New comorbidities, Anais Brasileiros De Dermatologia (2016)
- Psoriasis, National Institute of Health (2023)
- Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial, Journal of the American Academy of Dermatology (2023)
- Treatment of psoriasis in adults, UpToDate (2023)
- Topical calcineurin inhibitor and lymphoma risk: Evidence update with implication for daily practice, American Journal of Clinical Dermatology (2013)